Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Adrenergic amines, a class that includes agents such as epinephrine and ephedrine, have a well-established role in the management of respiratory conditions like Chronic Obstructive Pulmonary Disease (COPD). Their therapeutic effect is based on their ability to stimulate adrenergic receptors—primarily beta-2 adrenergic receptors—located in the smooth muscle of the airways. Activation of these receptors leads to bronchodilation, which relieves airway obstruction and reduces symptoms such as shortness of breath.

Modern COPD management guidelines, such as those from the Global Initiative for Chronic Obstructive Lung Disease (GOLD), emphasize the use of selective beta-2 agonists (e.g., albuterol, salmeterol, formoterol), which are chemically adrenergic amines. These agents are favored because they provide effective bronchodilation with a relatively favorable safety profile compared to non-selective adrenergic agonists (like epinephrine), which may cause more cardiovascular side effects.

While older, non-selective adrenergic amines (such as ephedrine and even inhaled or injected epinephrine) were historically used, their use has declined due to the development of more selective and safer beta-2 agonists. The efficacy and safety of these newer agents are supported by numerous randomized controlled trials and meta-analyses, which consistently demonstrate improvement in lung function, symptom scores, and quality of life for COPD patients. Therefore, the use of adrenergic amines, especially selective beta-2 agonists, in COPD is scientifically validated and forms a core part of pharmacologic therapy.

More about Adrenergic amines
More about Chronic Obstructive Pulmonary Disorder

Other ingredients used for Chronic Obstructive Pulmonary Disorder

Other health conditions supported by Adrenergic amines

Products containing Adrenergic amines